查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988494

CD抗原癌症治療市場：依治療方法、癌症類型和標靶分類－2026-2032年全球預測

CD Antigen Cancer Therapy Market by Therapy Type, Cancer Type, Targeted - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

CD抗原癌症治療市場預計到2025年將達到118.1億美元，到2026年將成長到125.9億美元，到2032年將達到192.2億美元，複合年成長率為7.19%。

主要市場統計數據
基準年 2025 118.1億美元
預計年份：2026年 125.9億美元
預測年份 2032 192.2億美元
複合年成長率 (%) 7.19%

對 CD 抗原標靶腫瘤治療方法進行權威概述，整合科學證據、臨床趨勢和商業化影響，供決策者參考。

以CD抗原為標靶的癌症治療融合了分子生物學、免疫工程和精準遞送技術，催生了新的治療方法。過去十年，轉化研究逐步揭示了哪些CD表面標誌物可用於選擇性區分惡性組織和正常組織，從而能夠設計出基於抗體的偶聯物、基因修飾細胞療法以及最佳化的生物製藥，在確保療效的同時控制毒性。

工程、監管和製造領域的整合創新如何重新定義 CD 抗原靶向腫瘤干預的路徑和商業性動態。

針對艱難梭菌抗原的癌症治療格局正在經歷一場變革，這主要得益於技術和製度層面的共同推動。標靶化載荷工程和連接子化學的進步提高了抗體藥物複合體的治療指數，從而增強了腫瘤選擇性並降低了脫靶效應。同時，新一代CAR-T細胞構建體融合了邏輯門控、強化細胞激素表達和關閉機制，將細胞療法的應用範圍從血液系統惡性腫瘤擴展到特定的固態腫瘤微環境。

我們將評估關稅政策的變化如何重塑艱難梭菌抗原癌症療法整個價值鏈的採購、製造地和業務永續營運。

預計2025年美國關稅政策的轉變將對CD抗原癌症療法相關的整個採購、生產和臨床供應鏈產生累積。進口試劑、一次性塑膠製品、特殊過濾膜和某些實驗室設備的關稅可能會逐步增加生物製藥生產和臨床試驗所需關鍵材料的接收成本。因此，各機構在早期專案中可能會面臨營運利潤率下降的壓力，以及處理測試樣本和生物製程耗材的可變成本增加。

基於細分的洞察揭示了治療方法和癌症適應症的組合如何決定開發複雜性、監管方法和商業化途徑。

細分市場分析揭示了每種治療方法和疾病適應症在研發路徑和策略重點上的顯著差異，這影響著臨床試驗設計、生產複雜性和商業化策略。根據治療方法類型，本研究對抗體藥物複合體(ADC)、嵌合體抗原受體 (CAR) T 細胞治療方法以及傳統生物製藥作用機制的整個過程。每種治療方法都有其獨特的需求。抗體藥物複合體(ADC) 需要先進的連接子和有效載荷最佳化，以及對腫瘤浸潤的可靠評估。 CAR T 細胞療法需要患者特異性細胞採集、體外操作和長期安全性監測。單株抗體則依賴成熟的生物製藥生產技術和大規模分銷管道。

區域管理體制、臨床生態系統和製造地如何影響全球差異化的研發和打入市場策略？

區域趨勢對艱難梭菌抗原療法的研發、取得和推廣軌跡有顯著影響，各主要區域的法規環境、臨床試驗系統和支付方考量各不相同。在美洲，大規模的臨床試驗能力、集中化的監管審查體係以及高度集中的專業治療中心正在加速一線人體試驗的啟動和商業化進程，同時，也需要強力的證據支持來應對支付方的審查。歐洲、中東和非洲（EMEA）的情況則較為複雜，集中式和國家監管要求並存，報銷途徑因市場而異，區域製造地在確保供應連續性和市場准入方面發揮戰略作用。亞太地區的特點是研發能力快速提升、國內生物技術生態系統不斷發展，以及法規結構日趨完善，越來越支持快速核准和本地化生產夥伴關係，因此，對於許多申辦方而言，亞太地區在生產和患者招募方面都是高度優先考慮的區域。

本書揭示了決定 CD 抗原腫瘤學競爭地位的企業級策略模式，包括如何確定夥伴關係、平台深度和生產規模。

CD抗原療法領域主要企業之間的競爭格局反映了平台專業化、策略聯盟和生產能力發展三者之間的相互作用。成熟的製藥公司擴大與高度專業化的創新企業合作或進行收購，以獲取尖端有效載荷、細胞工程平台和互補的診斷技術。這些合作關係通常包括共同投資擴大生產規模、共同開發契約的適應症以及平衡風險和潛在收益的許可模式。

為協調科學檢驗、生產靈活性和證據生成，以從艱難梭菌抗原療法中提取永續的商業性價值，提供實用的策略指南。

產業領導企業應採取整合策略，將科學重點與業務和商業性執行結合，以最大限度地發揮CD抗原標靶治療的潛力。首先，在研發早期階段優先考慮標靶檢驗和病患選擇策略，以降低後期臨床試驗成本高昂的風險，並增強對支付方和合作夥伴的價值提案。其次，透過將內部生產能力與成熟的契約製造合作夥伴結合，投資於生產柔軟性，以平衡規模、速度和品質保證，同時規避供應鏈中斷風險。

透明且可重複的混合方法，結合專家訪談、文獻整合和迭代檢驗，為嚴謹的市場洞察奠定了基礎。

本分析的調查方法融合了第一手資料和第二手資料，以確保研究的嚴謹性、多方驗證性以及對決策者的相關性。第一手資料包括對行業高管、臨床研究人員、生產專家和支付方進行結構化訪談，以了解他們對研發瓶頸、營運限制和商業性優先事項的真實觀點。第二手資料則整合了同行評審文獻、監管指導文件、臨床試驗註冊數據和企業資訊披露，以梳理技術趨勢、臨床進展和監管先例。

整合 CD 抗原療法的科學潛力和實際應用，並制定策略重點，將創新轉化為可及的癌症治療。

總之，針對艱難梭菌抗原的癌症治療方法處於腫瘤學創新戰略前沿，科學進步、生產技術革新和監管調整在此交匯融合，創造了意義重大的臨床機會。治療方法的固有複雜性與適應症帶來的臨床挑戰之間的相互作用，凸顯了製定個體化最佳化開發策略的必要性，這些策略需要在技術差異化和切實可行的營運計劃之間取得平衡。此外，貿易政策和區域監管差異等外部因素也會帶來結構性問題，這些問題會影響採購、生產在地化和實證策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：CD抗原癌症治療市場（依治療方法分類）

  • 抗體藥物複合體
  • 嵌合體抗原受體（CAR）T細胞療法
  • 單株抗體

第9章：CD抗原癌症治療市場（依癌症類型分類）

  • 骨髓惡性腫瘤
  • 固態腫瘤

第10章：Target 公司的 CD 抗原癌症治療市場

  • CD19
  • CD20
  • CD30
  • CD33
  • CD38
  • CD70

第11章：CD抗原癌症治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：CD抗原癌症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：CD抗原癌症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國艱難梭菌抗原癌症治療市場

第15章：中國大腸桿菌抗原癌症治療市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Illumina, Inc.
  • Incyte Corporation
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-9A2BA9536662

The CD Antigen Cancer Therapy Market was valued at USD 11.81 billion in 2025 and is projected to grow to USD 12.59 billion in 2026, with a CAGR of 7.19%, reaching USD 19.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.81 billion
Estimated Year [2026] USD 12.59 billion
Forecast Year [2032] USD 19.22 billion
CAGR (%) 7.19%

An authoritative overview of CD antigen-directed oncology approaches that synthesizes scientific rationale, clinical momentum, and commercialization implications for decision-makers

CD antigen-targeted cancer therapies represent a convergent space where molecular biology, immune engineering, and precision delivery technologies intersect to create new modalities of care. Over the past decade, translational research has progressively clarified which cluster of CD surface markers can be selectively exploited to distinguish malignant from healthy tissue, enabling the design of antibody-based conjugates, engineered cellular therapies, and optimized biologics that deliver efficacy while managing toxicity.

Clinical validation of multiple CD targets in hematological malignancies has catalyzed interest in expanding those approaches into solid tumors, where tumor microenvironment heterogeneity and antigen expression variability create additional complexities. Concurrently, manufacturing advances and regulatory adaptations have reduced development timelines for complex biologics, increasing the number of assets advancing into late-stage development. These shifts have broadened the stakeholder base to include not only specialized biotech innovators but also established pharmaceutical companies, contract manufacturing organizations, and specialized service providers.

Taken together, these dynamics position CD antigen-targeted approaches as a strategic priority for organizations pursuing durable, targeted oncology solutions. As a result, careful attention to translational science, clinical design, supply chain resilience, and payer engagement will be required to convert scientific promise into sustainable clinical and commercial impact.

How convergent innovations in engineering, regulation, and manufacturing are redefining the trajectory and commercial dynamics of CD antigen-targeted oncology interventions

The landscape for CD antigen cancer therapies is undergoing transformative shifts driven by convergent technological and systemic forces. Advances in targeted payload engineering and linker chemistry have enhanced the therapeutic index of antibody-drug conjugates, enabling higher tumor selectivity and reduced off-target effects. At the same time, next-generation CAR T-cell constructs that incorporate logic gating, armored cytokine expression, and off-switch mechanisms are extending the feasibility of cellular therapies beyond blood cancers and into certain solid tumor niches.

Parallel to scientific progress, regulatory frameworks are evolving to accommodate complex biologics, with agencies increasingly receptive to adaptive trial designs and real-world evidence to inform approval pathways. Manufacturing innovations such as decentralized production models, automation, and digital batch tracking are redefining scalability and quality control practices, thereby lowering operational friction for high-complexity therapies. In commercial terms, stakeholder expectations are shifting toward integrated care solutions that bundle diagnostics, access support, and long-term patient monitoring.

Consequently, organizations that align R&D priorities with flexible manufacturing, robust evidence generation, and collaborative payer strategies will be best positioned to capture opportunity in a landscape that rewards technical differentiation and patient-centered delivery models.

Assessing how tariff policy changes are reshaping sourcing, manufacturing footprints, and operational resilience across the CD antigen oncology value chain

The cumulative impact of tariff policy shifts in the United States in 2025 is expected to reverberate across procurement, manufacturing, and clinical supply networks involved in CD antigen cancer therapies. Tariffs on imported reagents, single-use plastics, specialized filtration membranes, and certain laboratory instruments can incrementally raise the landed cost of critical inputs required for biologics production and clinical trial execution. As a consequence, organizations may experience compressed operating margins on early-stage programs and face higher variable costs for trial sample handling and bioprocessing consumables.

Moreover, tariff-driven cost pressures can influence strategic sourcing decisions, prompting greater localization of supply chains and renewed investment in domestic manufacturing capacity. This pivot may improve supply reliability over time but often requires upfront capital expenditures and workforce development to shore up capabilities in sterility assurance, aseptic fill-finish, and cold chain logistics. In parallel, smaller developers and academic sponsors that lack integrated manufacturing may face amplified operational challenges, increasing the importance of contract manufacturing partnerships and collaborative procurement models.

In sum, tariff dynamics function as a structural variable that can reshape vendor selection, manufacturing footprints, and cost management strategies. Proactive scenario planning and strategic supplier engagement are therefore essential to mitigate short-term disruptions while capturing the long-term benefits of a more resilient and geographically diversified production ecosystem.

Critical segmentation-driven insights demonstrating how therapy modality and cancer indication jointly dictate development complexity, regulatory approach, and commercialization pathways

Segmentation analysis reveals meaningful differences in development pathways and strategic focus across modality and disease indications, with implications for clinical design, manufacturing complexity, and commercialization approaches. Based on Therapy Type, market is studied across Antibody-Drug Conjugates, Chimeric Antigen Receptor (CAR) T-cell Therapy, and Monoclonal Antibodies, which collectively span a continuum from targeted payload delivery to living cell modalities and classic biologic mechanisms. Each therapy type presents distinct requirements: antibody-drug conjugates necessitate advanced linker and payload optimization and robust tumor penetration assessments; CAR T-cell programs demand individualized cell collection, ex vivo manipulation, and long-term safety monitoring; monoclonal antibodies rely on well-established biologics manufacturing and large-scale distribution channels.

Based on Cancer Type, market is studied across Hematological Malignancies and Solid Tumors, categories that diverge in antigen accessibility, microenvironmental hurdles, and clinical endpoint expectations. Hematological malignancies often provide more uniform antigen expression and established response criteria, enabling faster proof-of-concept studies, whereas solid tumors require strategies to address antigen heterogeneity, stromal barriers, and intratumoral delivery. Together, these intersecting segmentation dimensions inform priorities for target selection, trial site networks, companion diagnostic needs, and post-market surveillance strategies. Accordingly, sponsors should tailor development plans to the modality-specific manufacturing pathways and the clinical complexities associated with the targeted cancer type.

How regional regulatory regimes, clinical ecosystems, and manufacturing footprints shape differentiated development and market entry strategies across global regions

Regional dynamics materially influence development, access, and adoption trajectories for CD antigen therapies, with differentiated regulatory environments, clinical trial ecosystems, and payer considerations across major geographies. In the Americas, sizable clinical trial capacity, centralized regulatory review structures, and a high concentration of specialized treatment centers accelerate first-in-human studies and commercial launches, while also necessitating robust evidence packages that address payer scrutiny. Europe, Middle East & Africa present a heterogeneous landscape where centralized and national regulatory requirements coexist, reimbursement pathways vary significantly by market, and regional manufacturing hubs can play a strategic role in addressing supply continuity and market access timelines. Asia-Pacific features rapidly expanding research capacity, growing domestic biotech ecosystems, and evolving regulatory frameworks that increasingly support expedited reviews and localized manufacturing partnerships, making the region both a production and patient recruitment priority for many sponsors.

These regional characteristics affect strategic choices about trial site selection, regulatory filings, and commercial deployment. Sponsors should consider leveraging regional centers of excellence for complex therapy delivery, aligning evidence generation with diverse payer expectations, and planning manufacturing footprints that reduce logistical risk while optimizing time to patient.

Strategic company-level patterns that reveal how partnerships, platform depth, and manufacturing scale determine competitive positioning in CD antigen oncology

Competitive dynamics among leading companies in the CD antigen therapy arena reflect a mix of platform specialization, strategic collaborations, and manufacturing capability development. Established pharmaceutical companies are increasingly partnering with or acquiring specialized innovators to access cutting-edge payloads, cell engineering platforms, and diagnostic complements. These collaborations often include shared investments in manufacturing scale-up, co-development agreements to expand indications, and licensing models that balance risk with potential upside.

Smaller biotechs and cell therapy pioneers continue to drive scientific differentiation through novel antigen targeting, multi-specific constructs, and improved safety switches for cellular products. At the same time, specialized contract service providers and manufacturing partners have expanded capacity and expertise to support complex biologics and autologous therapy workflows, offering modular solutions that allow sponsors to accelerate timelines without fully internalizing capital-intensive production. Overall, successful organizations demonstrate a blend of technological depth, robust clinical development strategies, and an operational focus on quality systems, regulatory readiness, and supply chain resilience that together enable sustained advancement from R&D through commercialization.

Actionable strategic directives that align scientific validation, manufacturing agility, and evidence generation to unlock durable commercial value from CD antigen therapies

Industry leaders should adopt an integrated strategy that aligns scientific prioritization with operational and commercial execution to maximize the potential of CD antigen-targeted therapies. First, prioritize target validation and patient selection strategies early in development to de-risk expensive late-stage studies and to strengthen the value proposition for payers and partners. Second, invest in manufacturing flexibility by combining internal capabilities with validated contract manufacturing partners to balance scale, speed, and quality assurance while hedging against supply chain disruptions.

Third, design evidence-generation plans that incorporate prospective real-world data collection and adaptive trial elements to support regulatory dialogue and payer negotiations. Fourth, pursue strategic partnerships that couple complementary platforms-such as combining antibody-drug conjugate expertise with novel payload chemistry or pairing cell therapy engineering with scalable manufacturing platforms-to accelerate time to proof-of-concept. Finally, build multidisciplinary commercialization playbooks that include diagnostic alignment, long-term safety monitoring plans, and patient support services to facilitate adoption and reimbursement. By executing on these pragmatic, coordinated actions, companies can convert technological promise into durable clinical and commercial outcomes.

A transparent and reproducible mixed-methods approach combining expert interviews, literature synthesis, and iterative validation to underpin rigorous market insights

The research methodology underpinning this analysis integrates primary and secondary approaches to ensure rigor, triangulation, and relevance to decision-makers. Primary research included structured interviews with industry executives, clinical investigators, manufacturing experts, and payers to capture real-world perspectives on development bottlenecks, operational constraints, and commercial priorities. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map technological trends, clinical progress, and regulatory precedent.

Data synthesis employed cross-validation techniques and expert panels to reconcile divergent views and to test scenario assumptions. The methodology emphasized transparency in source attribution, iterative expert review cycles, and sensitivity checks to highlight areas of consensus and uncertainty. Limitations include rapidly evolving clinical data streams and region-specific regulatory changes that may alter the competitive landscape; consequently, the analysis is designed to be operationalized through periodic updates, targeted follow-up interviews, and tailored workshops that extend the core findings into bespoke strategic plans.

A synthesis that distills the scientific promise and operational realities of CD antigen therapies into strategic priorities for translating innovation into accessible oncology care

In conclusion, CD antigen-targeted cancer therapies occupy a strategic frontier of oncology innovation where scientific advances, manufacturing evolution, and regulatory adaptation converge to create meaningful clinical opportunities. The interplay between modality-specific complexities and indication-driven clinical challenges underscores the need for tailored development strategies that balance technical differentiation with pragmatic operational planning. Moreover, external factors such as trade policy and regional regulatory divergence introduce structural considerations that can influence sourcing, manufacturing localization, and evidence strategies.

Organizations that integrate robust target validation, flexible manufacturing partnerships, and proactive payer-engagement plans will be well-positioned to navigate the emerging landscape. Ultimately, success in this domain requires a systems-level perspective that aligns translational science, clinical design, and commercial execution to deliver therapies that are not only effective but also accessible and sustainable for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CD Antigen Cancer Therapy Market, by Therapy Type

  • 8.1. Antibody-Drug Conjugates
  • 8.2. Chimeric Antigen Receptor (CAR) T-cell Therapy
  • 8.3. Monoclonal Antibodies

9. CD Antigen Cancer Therapy Market, by Cancer Type

  • 9.1. Hematological Malignancies
  • 9.2. Solid Tumors

10. CD Antigen Cancer Therapy Market, by Targeted

  • 10.1. CD19
  • 10.2. CD20
  • 10.3. CD30
  • 10.4. CD33
  • 10.5. CD38
  • 10.6. CD70

11. CD Antigen Cancer Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. CD Antigen Cancer Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. CD Antigen Cancer Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States CD Antigen Cancer Therapy Market

15. China CD Antigen Cancer Therapy Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AbbVie Inc.
  • 16.6. Alexion Pharmaceuticals, Inc.
  • 16.7. Amgen Inc.
  • 16.8. AstraZeneca PLC
  • 16.9. Bayer AG
  • 16.10. Biogen Inc.
  • 16.11. Bristol-Myers Squibb Company
  • 16.12. Celgene Corporation
  • 16.13. Eli Lilly and Company
  • 16.14. Exelixis, Inc.
  • 16.15. Genmab A/S
  • 16.16. Gilead Sciences, Inc.
  • 16.17. Illumina, Inc.
  • 16.18. Incyte Corporation
  • 16.19. Jazz Pharmaceuticals PLC
  • 16.20. Johnson & Johnson
  • 16.21. Merck & Co., Inc.
  • 16.22. Novartis AG
  • 16.23. Pfizer Inc.
  • 16.24. Regeneron Pharmaceuticals, Inc.
  • 16.25. Roche Holding AG
  • 16.26. Sanofi SA
  • 16.27. Seagen Inc.
  • 16.28. Takeda Pharmaceutical Company Limited
  • 16.29. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD30, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD30, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD30, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD33, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD33, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD33, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD38, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD38, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD38, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD70, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD70, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD70, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 76. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 88. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 92. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)